2017 tables: Institutions - life sciences - corporate

The 2017 tables are based on Nature Index data from 1 January 2016 to 31 December 2016.

Table criteria

# Institution Share 2015 Share 2016 Count 2016 Change in Adjusted Share 2015-2016*
1 Novartis International AG, Switzerland 37.45 33.57 100 -7.8%
2 F. Hoffmann-La Roche AG, Switzerland 37.91 30.57 73 -17.1%
3 AstraZeneca plc, United Kingdom (UK) 14.40 18.28 58 30.6%
4 Pfizer Inc., United States of America (USA) 10.68 15.37 39 48.0%
5 Amgen Inc., United States of America (USA) 11.50 13.48 44 20.6%
6 Eli Lilly and Company, United States of America (USA) 7.53 7.98 34 9.1%
7 GlaxoSmithKline plc. (GSK), United Kingdom (UK) 17.77 7.34 40 -57.5%
8 Merck & Co., Inc., United States of America (USA) 10.24 7.06 35 -29.1%
9 BGI, China 12.97 5.60 31 -55.6%
10 Johnson & Johnson, United States of America (USA) 6.05 5.15 20 -12.5%
11 Leidos Holdings, Inc., United States of America (USA) 3.97 4.98 60 28.9%
12 E. I. du Pont de Nemours and Company (DuPont), United States of America (USA) 1.42 4.64 9 235.0%
13 Regeneron Pharmaceuticals, Inc., United States of America (USA) 4.43 4.57 10 6.3%
14 Bayer AG, Germany 0.74 4.02 20 459.5%
15 Constellation Pharmaceuticals, Inc., United States of America (USA) 4.00 6 N/A
16 Formosa Plastics Group, Taiwan 5.09 3.95 18 -20.2%
17 Alphabet Inc., United States of America (USA) 0.34 3.87 14 1,081.4%
18 C. H. Boehringer Sohn AG & Co. KG (Boehringer Ingelheim), Germany 1.34 3.69 9 183.9%
19 Ionis Pharmaceuticals, Inc., United States of America (USA) 4.78 3.58 19 -23.0%
20 Bristol-Myers Squibb (BMS), United States of America (USA) 6.31 3.57 16 -41.7%
21 Novo Nordisk A/S, Denmark 2.23 3.19 9 47.6%
22 Samsung Group, South Korea 3.29 2.98 25 -6.7%
23 Biogen Inc., United States of America (USA) 1.36 2.74 14 107.4%
24 Illumina, Inc., United States of America (USA) 3.87 2.71 21 -27.9%
25 Advanced Telecommunications Research Institute International (ATR), Japan 0.83 2.47 9 204.8%
26 Nestlé S.A., Switzerland 1.17 2.20 10 94.4%
27 Sanofi, France 6.43 2.11 21 -66.3%
28 Sosei Co., Ltd., Japan 2.00 2 N/A
29 Gilead Sciences, Inc., United States of America (USA) 2.19 1.94 8 -9.1%
30 23andMe, Inc., United States of America (USA) 1.78 1.82 14 5.1%
31 GeneDx Inc., United States of America (USA) 0.70 1.80 16 165.9%
32 BASF SE, Germany 0.77 1.72 3 130.8%
33 Merck KGaA, Germany 1.15 1.68 7 50.5%
34 Pacific Biosciences of California, Inc., United States of America (USA) 1.44 1.65 10 18.0%
35 Thermo Fisher Scientific Inc., United States of America (USA) 2.00 1.62 14 -16.6%
36 New England Biolabs, Inc. (NEB), United States of America (USA) 5.18 1.57 5 -68.9%
37 Eisai Co., Ltd., Japan 0.25 1.56 6 541.2%
38 Genmab B.V., Netherlands 1.51 3 N/A
39 Peloton Therapeutics, Inc., United States of America (USA) 1.48 3 N/A
40 Synthetic Genomics, Inc. (SGI), United States of America (USA) 1.40 3 N/A
41 Dynavax Technologies Corp., United States of America (USA) 0.03 1.33 3 3,989.1%
42 Integral Molecular, Inc., United States of America (USA) 0.54 1.29 4 143.7%
43 Microsoft Corporation, United States of America (USA) 0.90 1.28 7 46.8%
44 Kolltan Pharmaceuticals, Inc., United States of America (USA) 0.56 1.25 2 131.5%
45 Momenta Pharmaceuticals, Inc., United States of America (USA) 1.09 1.24 2 17.7%
46 Merrimack Pharmaceuticals, Inc., United States of America (USA) 1.21 2 N/A
47 Dow AgroSciences, United States of America (USA) 1.20 5 N/A
48 Ablynx N.V., Belgium 1.19 2 N/A
49 Oncomed Pharmaceuticals, Inc., United States of America (USA) 1.17 2 N/A
50 10x Genomics, United States of America (USA) 1.12 3 N/A

Footnote

Each year, the Nature Index publishes tables based on counts of high-quality research outputs in the previous calendar year. Users please note:

  1. The data behind the tables are based on a relatively small proportion of total research papers, they cover the natural sciences only and outputs are non-normalized (that is, they don’t reflect the size of the country or institution, or its overall research output).
  2. The Nature Index is one indicator of institutional research performance. The metrics of Count and Share used to order Nature Index listings are based on an institution’s or country’s publication output in 82 natural-science journals, selected on reputation by an independent panel of leading scientists in their fields.
  3. Nature Index recognizes that many other factors must be taken into account when considering research quality and institutional performance; Nature Index metrics alone should not be used to assess institutions or individuals.
  4. Nature Index data and methods are transparent and available under a creative commons licence at natureindex.com.

The Nature Index database undergoes regular updating, corrections, adjustment of institutional hierarchies, and removal of retracted papers and thus the live website can differ from the frozen annual tables.

*The change in adjusted Share accounts for the small annual variation in the total number of articles in Nature Index journals. Share values have been adjusted to 2020 levels to calculate the percentage change. For more information on the adjustment, please see the Adjusted metric explainer.